Centre to discontinue allocation of anti-Black Fungus drug
The Hindu
Advises States, UTs to procure from manufacturers
The Centre has decided to discontinue allocation of anti-Mucormycosis drug Liposomal Amphotericin B to States and Union Territories in view of decline in fresh cases of the fungal infection as well as improved availability of the medicine. “As the number of active patients have come down and supply position of the medicine has also improved considerably, it is felt that there is no more need and justification for allocation of Liposomal Amphotericin B to States and Union Territories,” the Department of Pharmaceuticals said. Conveying the decision to discontinue allocation, the Department in a communication to the Health Secretaries of States and Union Territories recently said the drug can be procured, as per their requirements, from the manufacturers and importers. The move marks a significant change from the situation prevailing a few months ago when a sharp increase in number of people contracting Mucormycosis or Black Fungus led to demand for the drug also soaring.More Related News